Safety of mRNA COVID-19 vaccinations in patients with allergic diseases

https://systems.jhu.edu/research/public-health/ncov/[access: 4.April.2022.]. Kirtipal, 2020, From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses, Infect. Genet. Evol., 85, 10.1016/j.meegid.2020.104502 V'kovski, 2021, Coronavirus biology and replication: implications for SARS-CoV-2, Nat. Rev. Microbiol., 19, 155, 10.1038/s41579-020-00468-6 Wang, 2020, SARS-CoV-2: structure, biology, and structure-based therapeutics development, Front. Cell. Infect. Microbiol., 10, 10.3389/fcimb.2020.587269 Campos, 2020, SARS-CoV-2 virus infection: targets and antiviral pharmacological strategies, J. Evid. Base Med., 13, 255, 10.1111/jebm.12414 Dinnes, 2020, Cochrane COVID-19 Diagnostic Test Accuracy Group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection, Cochrane Database Syst. Rev., 8 Zost, 2020, Potently neutralizing and protective human antibodies against SARS-CoV-2, Nature, 584, 443, 10.1038/s41586-020-2548-6 Zhang, 2020, SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity, Nat. Commun., 11, 6013, 10.1038/s41467-020-19808-4 Barnes, 2020, SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies, Nature, 588, 682, 10.1038/s41586-020-2852-1 Liu, 2021, Antibody responses against SARS-CoV-2 in COVID-19 patients, J. Med. Virol., 93, 144, 10.1002/jmv.26241 Park, 2021, mRNA vaccines for COVID-19: what, why and how, Int. J. Biol. Sci., 17, 1446, 10.7150/ijbs.59233 Hyde, 2015, Innate immune restriction and antagonism of viral RNA lacking 2׳-O methylation, Virology, 479–480, 66, 10.1016/j.virol.2015.01.019 Tanguay, 1996, Translational efficiency is regulated by the length of the 3' untranslated region, Mol. Cell Biol., 16, 146, 10.1128/MCB.16.1.146 Risma, 2021, Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines, J. Allergy Clin. Immunol., 147, 2075, 10.1016/j.jaci.2021.04.002 Shimabukuro, 2021, Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine, JAMA, 325, 780, 10.1001/jama.2021.0600 2021, Food and Drug Administration Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021, MMWR Morb. Mortal. Wkly. Rep., 70, 125, 10.15585/mmwr.mm7004e1 2010, Joint task force on practice parameters; American academy of allergy, asthma and Immunology; American college of allergy, asthma and Immunology; joint council of allergy, asthma and Immunology. Drug allergy: an updated practice parameter, Ann. Allergy Asthma Immunol., 105, 259 Barni, 2020, Immunoglobulin E (IgE)-Mediated food allergy in children: epidemiology, pathogenesis, diagnosis, prevention, and management, Medicina (Kaunas), 56, 111, 10.3390/medicina56030111 Szebeni, 2014, Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals, Mol. Immunol., 61, 163, 10.1016/j.molimm.2014.06.038 Kozma, 2020, Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals, Adv. Drug Deliv. Rev., 154–155, 163, 10.1016/j.addr.2020.07.024 Chanan-Khan, 2003, Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions, Ann. Oncol., 14, 1430, 10.1093/annonc/mdg374 Bavli, 2019, Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs, J. Contr. Release, 306, 138, 10.1016/j.jconrel.2019.06.007 Szebeni, 2011, Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention, Adv. Drug Deliv. Rev., 63, 1020, 10.1016/j.addr.2011.06.017 Tretiakova, 2022, Liposomes as adjuvants and vaccine delivery systems, Biochem (Mosc) Suppl Ser A Membr Cell Biol., 16, 1 Garvey, 2021, Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?, Br. J. Anaesth., 126, e106, 10.1016/j.bja.2020.12.020 Bender, 2017, Factor XII-driven inflammatory reactions with implications for anaphylaxis, Front. Immunol., 8, 1115, 10.3389/fimmu.2017.01115 Kaplan, 2014, Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway, Adv. Immunol., 121, 41, 10.1016/B978-0-12-800100-4.00002-7 Kuder, 2021, Anaphylaxis to vaccinations: a review of the literature and evaluation of the COVID-19 mRNA vaccinations, Cleveland Clinic Journal of Medicine Mar, 10.3949/ccjm.88a.ccc075 Greenhawt, 2021, The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, grade assessment, and international consensus approach, J. Allergy Clin. Immunol. Pract., 9, 3546, 10.1016/j.jaip.2021.06.006 Anand, 2021, Potential therapeutic targets and vaccine development for SARS-CoV-2/COVID-19 pandemic management: a review on the recent update, Front. Immunol., 12, 10.3389/fimmu.2021.658519